Full Press Release Details
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
LONDON, May 13, 2024 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing
next-generation programmed T cell therapies, today announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission later this week with regard to
its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the Q1 2024 10-Q ). Form 12b-25 will
allow the Company an automatic extension of five additional calendar days to file the Q1 2024 10-Q which is due on May 15, 2024.
In accordance with today s announcement, the Company is canceling its previously announced earnings release and call scheduled for before U.S. market
open on May 14, 2024. The Company expects to file the Q1 2024 10-Q as soon as practicable and no later than the May 20, 2024 deadline in compliance with Rule
12b-25. The Company has rescheduled its first quarter 2024 conference call and webcast to now be held on May 17, 2024 at 8:30 am EDT/1:30 pm BST to discuss the Company s financial results and
provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are
required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus website.
S.A. Noonan Communications